louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT03743545: Assessment of Heat Generation From Low Speed Drilling Without Irrigation
Official title: ASSESSEMENT OF LOW SPEED DRILLING WITHOUT IRRIGATION VERSUS CONVENTIONEL DRILLING WITH IRRIGATION REGARDING HEAT GENERATION AND PERI-IMPLANT MARGINAL BONE LOSS
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Implant Site Reaction
Lead sponsor: Cairo University
Sponsor class: OTHER
First posted: 2018-11-16
Enrollment: 2
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: healthy posterior mandible
Primary purpose: TREATMENT

Brief summary: ASSESSMENT OF LOW SPEED DRILLING WITHOUT IRRIGATION VERSUS CONVENTIONAL DRILLING WITH IRRIGATION REGARDING HEAT GENERATION AND PERI-IMPLANT MARGINAL BONE LOSS

Detailed description: Assessment of heat generation from conventional drilling speed for dental implant placement versus biological drilling (low speed without irrigation ) by thermocouples technology And measure the primary stability of dental implants placed by the two techniques by osstel device

Eligibility criteria: Inclusion Criteria: both sex no intraoral soft and hard tissue pathology no systemic condition that contraindicate implant placement adult patients with proper posterior mandibular ridge requires implant placement

Exclusion Criteria:

presence of pathological lesions heavy smokers more than 20 cigarettes per day patients with systemic disease that may affect normal healing Patients with no enough bone in posterior mandible for implant placement

Primary outcomes:
measure: Measurement of heat generation from low speed hand piece drills drilling by thermocouple technology
timeFrame: 6 months
Secondary outcomes:
measure: stability-osstell device to assess the primary stability of placed dental implant
timeFrame: 6 months
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT00271245: Selenium Supplementation of Patients With Cirrhosis
Official title: Selenium Supplementation of Patients With Cirrhosis
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: NA
Conditions: Liver Disease
Keywords: cirrhosis
liver disease
selenium
selenoproteins
selenoprotein P
biomarkers
Lead sponsor: Vanderbilt University
Sponsor class: OTHER
Collaborators: name: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
First posted: 2005-12-30
Enrollment: 99
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to determine whether patients with liver cirrhosis can improve their selenium nutritional status by taking supplemental selenium.

Detailed description: Selenium is an essential nutrient. Selenium carries out its biological functions through selenoproteins. The liver converts dietary selenium to a form that can be used to make selenoproteins. Patients with cirrhosis have much lower selenium levels than healthy individuals. We hypothesize that patients with cirrhosis are unable to utilize dietary selenium for selenoprotein synthesis. These patients may benefit from another form of selenium: selenate.

We will compare the effects of two supplemental forms of selenium on plasma selenium levels in patients with cirrhosis. Patients will be randomized to receive either a placebo, 200 µg selenomethionine, 200 µg selenate or 400 µg selenate, daily, for 8 weeks. We will measure selenium levels in the blood at baseline, week 4 and week 8. We will determine which forms of selenium, if any, increased plasma selenium levels of the cirrhosis patients.

Eligibility criteria: Inclusion Criteria:

* liver disease
* aged 18 or above

Exclusion Criteria:

* substance abuse
* renal failure

Primary outcomes:
measure: Plasma selenoprotein P, Plasma GPX-3 activity, Total plasma selenium
timeFrame: 8 week
Secondary outcomes:
Other outcomes:
Locations:
city: Nashville
country: United States
facility: Vanderbilt University Medical Center
state: Tennessee
Study officials:
affiliation: Vanderbilt University
name: Raymond F Burk, M.D.
role: PRINCIPAL_INVESTIGATOR
References:
citation: Burk RF, Hill KE, Motley AK, Byrne DW, Norsworthy BK. Selenium deficiency occurs in some patients with moderate-to-severe cirrhosis and can be corrected by administration of selenate but not selenomethionine: a randomized controlled trial. Am J Clin Nutr. 2015 Nov;102(5):1126-33. doi: 10.3945/ajcn.115.110932. Epub 2015 Oct 14.
Clinical trial NCT03555045: The Effect of Slanted Recession of Horizontal Muscle on Horizontal Strabismus With Abnormal Accommodative Convergence /Accommodation Ratio (AC/A)
Official title: The Effect of Slanted Recession of Horizontal Muscle on Horizontal Strabismus With Abnormal Accommodative Convergence /Accommodation Ratio (AC/A)
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE2
PHASE3
Conditions: Horizontal Strabismus With High AC/A Ratio
Lead sponsor: Shahid Beheshti University of Medical Sciences
Sponsor class: OTHER
First posted: 2018-06-13
Enrollment: 100
Sex: ALL
Minimum age (years): 6
Maximum age (years): 80
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Different methods was tried to treat high AC/A strabismus cases;such as prescription of bifocal glasses in esotropia,recession of horizontal muscles with posterior fixation sutures,more recession than needed for far deviation(augmented recession),recession and pulley fixation and slant recession.

Different results was reported for any type of above methods. In recent studies,slanted recession was applied for high AC/A in esotropic cases and success rate of 67% was reported.but there was no unanimity for procedure of choice.

Since slant recession method is simpler and has low side effect than the other methods,therefore in this study the investigators want to peruse the outcome of this method on high AC/A horizontal strabismus.


Eligibility criteria: Inclusion Criteria:

* all patients with horizontal strabismus that the different between far deviation and near deviation is more than 10 pd

Exclusion Criteria:

* all patients who had history of surgery on horizontal muscles and patients with pseudo high AC/A ratio.

Primary outcomes:
measure: far-near deviation difference
timeFrame: 90 days after surgery
Secondary outcomes:
measure: success rate of surgery
timeFrame: 90 days after surgery
Other outcomes:
Locations:
city: Tehran
country: Iran, Islamic Republic of
facility: Ophthalmic Research Center
Study officials:
References:
Clinical trial NCT02177045: Breast Lesions Characterization on Contrast Enhanced Ultrasound With Histopathological Correlation
Official title: Breast Lesions Characterization on Contrast Enhanced Ultrasound With Histopathological Correlation
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Malignant Neoplasm, Overlapping Lesion of Breast
Lead sponsor: Rambam Health Care Campus
Sponsor class: OTHER
First posted: 2014-06-27
Enrollment: 50
Sex: FEMALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: DIAGNOSTIC

Brief summary: Breast lesions are a common condition, diagnosed by imaging and palpation. In order to reduce the number of biopsies performed to the definitive diagnosis of a breast lesion, an imaging method with a high degree of accuracy is needed. Ultrasound imaging with microbubbles contrast media allows the diagnosis of vascularization of the lesion, according to timing. Our hypothesis is that a highly vascularized lesion that enhances in an early timing is most likely to represent a malignant lesion and thus, deserves biopsy for a definitive diagnosis. Females over 18 years age, with a focal lesion in breast will be suitable to perform this examination.


Eligibility criteria: Inclusion Criteria:

* Female with a diagnosed breast focal lesion

Exclusion Criteria:

* Allergic conditions to contrast media,
* asthma,
* R-L shunt

Primary outcomes:
measure: Tumor vascularization
timeFrame: one year
Secondary outcomes:
Other outcomes:
Locations:
city: Haifa
country: Israel
facility: Ultrasound Unit Imaging Dept Rambam Health Care Campus
Study officials:
affiliation: Rambam Health Care Center
name: Diana Gaitini, Prof
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06456645: Effects of Smoking on Placenta and Lactation
Official title: The Impacts of Maternal Smoking During Pregnancy on Breastfeeding and the Correlation of IGF, Leptin, HPL Expression in Placenta Tissue
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Smoking, Tobacco
Placenta Diseases
Breastfeeding
Fetal Conditions
Keywords: Smoking cigarette
placenta
IGF-1
Leptin
HPL
breastfeeding
Lead sponsor: Celal Bayar University
Sponsor class: OTHER
First posted: 2024-06-13
Enrollment: 70
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 45
Standard ages: ADULT
Accepts healthy volunteers: yes
Observational model: CASE_CONTROL
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Pregnant women who have started smoking at least 100 cigarettes in her lifetime and who now smokes every day

Brief summary: Maternal smoking during pregnancy although it is known to be associated with fetal growth restriction, it's effect on postpartum breastfeeding is not yet clear. The aim of the present study was to examine the impacts of smoking in pregnancy on breastfeeding as well as its impacts on placental immunoreactivity.

Detailed description: The study was conducted on 70 women who gave birth via spontaneous vaginal delivery. Groups were classified as Smokers (n=35) and Non-smokers (n=35). The breastfeeding conditions of both groups were evaluated prior to discharge and after postpartum 10th day.

Cross-sections were taken from the placenta tissues after which their IGF-1 (insulin like growth factor-1), Leptin, HPL (human placental lactogen) immunoreactivities were examined.

Eligibility criteria: Inclusion Criteria:

* Pregnant women who have started smoking at least 100 cigarettes in her lifetime and who now smokes every day,
* Pregnant women who have never smoked throughout their life, including pregnancy(16),
* Pregnant women who gave birth at term,
* Multiple pregnancy, preeclampsia, gestational diabetes, thyroid dysfunction, those who do not have a systemic disease and due to systemic disease during pregnancy those who do not use
* Pregnant women who had spontaneous vaginal delivery,
* In order not to encounter communication barriers and because cultural differences may vary, the pregnant woman is not a foreign national,
* Pregnant women who do not have any barriers to communication by phone,
* Those who do not have any health problems that prevent breastfeeding

Exclusion Criteria:

* multiple pregnancy
* insulin dependent diabetes
* pregnant women who have had a cesarean section
* preeclampsia
* thyroid disease

Primary outcomes:
measure: 100% Patients's placenta with smoking in Pregnancy and 100% Patients's Placenta with from non-smoking in Pregnancy. Placenta Tissues Staining Measured by immunohistochemistry and biochemistry technique.
timeFrame: Baseline
Secondary outcomes:
measure: Sociodemographic, birth history, and breastfeeding questions were measured by survey technique.
timeFrame: Baseline
Other outcomes:
Locations:
city: Manisa
country: Turkey
facility: Manisa Celal Bayar Universitesi
Study officials:
References:
Clinical trial NCT02546245: Modification and Evaluation of the Educational Mobile Games Heroes of Knowledge in Children
Official title: Modification and Evaluation of the Educational Mobile Games Heroes of Knowledge in Children
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Math Knowledge
Lead sponsor: Yale University
Sponsor class: OTHER
First posted: 2015-09-10
Enrollment: 133
Sex: ALL
Minimum age (years): 5
Maximum age (years): 8
Standard ages: CHILD
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL

Brief summary: The goal of the proposed research is to adapt and rigorously evaluate educational mobile games, designed as a downloadable mobile apps to be played on smartphones or tablets. Investigators will be partnering with Yogome for this project. Yogame is a company dedicated to creating educational games that aim to reinforce knowledge acquired in school and help children learn new things in an entertaining and fun way.

Detailed description: This study will modify and evaluate the Heroes of Knowledge (HoK) games, beginning with the Math Heroes game which was designed to be played for up to 8 hours. Other games in the HoK series may be included in this process if they are fully developed and available for testing. In testing the efficacy of the Math Heroes game, children will play the game for 1-1.5 hours per week, 2-3 times per week, for 2-4 weeks (to accumulate 6-8 hours of game play). The game has been designed to target math knowledge skills identified by the Common Core Standards for Mathematics (2012).

Eligibility criteria: Inclusion Criteria:

* Participants must be in first grade and interested and able to participate in a mobile app-based videogame (willing to sit with a tablet computer for approximately 1-1.5 hours, 2-3 times per week for 2-4 weeks).

Exclusion Criteria:

* None

Primary outcomes:
measure: Pearson KeyMath3 Diagnostic Assessment (KeyMath-3DA)
timeFrame: Baseline
measure: Pearson KeyMath3 Diagnostic Assessment (KeyMath-3DA)
timeFrame: 2-4 weeks
Secondary outcomes:
measure: Academic Self Competence will be captured using a "structure alternate format" scale
timeFrame: Baseline
measure: Academic Self Competence will be captured using a "structure alternate format" scale
timeFrame: 2-4 weeks
Other outcomes:
Locations:
city: New Haven
country: United States
facility: Yale University
state: Connecticut
Study officials:
affiliation: Yale University
name: Lynn E Fiellin, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02674945: Understanding and Improving Quality of Life Through a Wireless Activity Tracker: Observational Phase
Official title: Understanding and Improving Quality of Life Through a Wireless Activity Tracker: Observational Phase
Study type: OBSERVATIONAL
Overall status: TERMINATED
Conditions: Brain Tumor
Keywords: fitbit
activity tracker
sleep
quality of life
Lead sponsor: University of Minnesota
Sponsor class: OTHER
First posted: 2016-02-05
Enrollment: 29
Sex: ALL
Minimum age (years): 18
Maximum age (years): 99
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Consentable patients suffering from a single or multiple primary or metastatic brain tumors

Brief summary: This project attempts to correlate wireless activity data with quality of life and sleep surveys in order to find a new method of monitoring patients during their treatment.

Detailed description: This project proposes the investigation, validation, and use of a wireless activity tracker to better understand and improve the quality of life of patients suffering from brain tumors. The Fitbit flex wireless syncing activity tracker will be distributed to 75 patients, and the electronic infrastructure to automatically track patients will be created and adapted for the cohort. Surveys will routinely assess the ease-of-use and any problems arising. This heterogenous population of patients suffering from brain tumors will be tracked and compared through routine evaluation of their quality of life through well-established surveys, including the SF-36 and FACT-Br. The association between data recorded from the activity tracker and the QOL surveys will be quantified to validate the activity tracking data as a surrogate measure of part, if not all, of QOL as well as sleep.

Eligibility criteria: Inclusion Criteria:

* diagnosed with primary or metastatic brain tumor
* able to wear wireless activity tracker
* able to complete QOL and sleep surveys every 3 months

Exclusion Criteria:

* unable to provide consent
* age \< 18
* lack of use of the wireless activity tracker for more than 2 consecutive months

Primary outcomes:
measure: Activity measured in steps
timeFrame: 1 year delineated by minute
Secondary outcomes:
measure: Sleep
timeFrame: per night over 1 year
measure: Quality of Life - SF-36
timeFrame: months 0, 3, 6, 9, and 12
measure: Quality of Life - Fact- Br
timeFrame: months 0, 3, 6, 9, and 12
Other outcomes:
Locations:
city: Minneapolis
country: United States
facility: University of Minnesota
state: Minnesota
Study officials:
affiliation: University of Minnesota
name: David Darrow, MD MPH
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00737945: Prognostic Value of Endothelial Dysfunction and Coronary Complexity
Official title: Incremental Significance of Endothelial Function Assessed by Reactive Hyperemia Peripheral Arterial Tonometry to Improve Risk Stratification in High Risk Patients for Cardiovascular Events
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Cardiovascular Disease
Lead sponsor: Kumamoto University
Sponsor class: OTHER
First posted: 2008-08-20
Enrollment: 1000
Sex: ALL
Minimum age (years): 30
Maximum age (years): 90
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Kumamoto University Hospital and Yokohama City University Medical Center

Brief summary: The investigators test the additional clinical value of the physiological assessment of endothelial function to the morphological assessment of coronary complexity and classical risk score in predicting cardiovascular events.

Detailed description: The investigators enroll consecutive, stable high risk patients for cardiovascular events. The reactive hyperemia peripheral arterial tonometry index (RHI) was measured before coronary angiography and coronary lesions were assessed angiographically by SYNTAX Scoring system. The investigators all subjects and examined the occurrence of cardiovascular events (CV death, non-fatal myocardial infarction and ischemic stroke, unstable angina pectoris, hospitalization for HF, coronary revascularization, or non-fatal aortic and peripheral vascular disease).

Eligibility criteria: Inclusion Criteria:

* Stable, high-risk patients with diabetes mellitus, or more than two conventional coronary risk factors, who are referred for coronary angiography because of angina-like chest symptoms.

Exclusion Criteria:

* An ejection fraction \< 50%
* Moderate to severe valvular heart disease
* Cardiomyopathy
* Allergy to latex
* Significant endocrine, hepatic, renal, or inflammatory disease
* cerebrovascular disease

Primary outcomes:
measure: Cardiovascular event
timeFrame: Outcome is assessed 1 to 4 years after entry
Secondary outcomes:
Other outcomes:
Locations:
city: Kumamoto
country: Japan
facility: Kumamoto University Hospital
Study officials:
References:
citation: Matsuzawa Y, Sugiyama S, Sumida H, Sugamura K, Nozaki T, Ohba K, Matsubara J, Kurokawa H, Fujisue K, Konishi M, Akiyama E, Suzuki H, Nagayoshi Y, Yamamuro M, Sakamoto K, Iwashita S, Jinnouchi H, Taguri M, Morita S, Matsui K, Kimura K, Umemura S, Ogawa H. Peripheral endothelial function and cardiovascular events in high-risk patients. J Am Heart Assoc. 2013 Nov 25;2(6):e000426. doi: 10.1161/JAHA.113.000426.
Clinical trial NCT06821945: A Clinical Trial to Evaluate the Safety and Efficacy of Olanzapine Titration Schedule in Patients With Schizophrenia
Official title: A Multi-Center, Randomized, Double-Blind, Parallel-Design, Exploratory Clinical Trial to Evaluate the Safety and Efficacy of Olanzapine Titration Schedule in Patients With Schizophrenia
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: PHASE2
Conditions: Schizophrenia
Lead sponsor: Boryung Pharmaceutical Co., Ltd
Sponsor class: INDUSTRY
First posted: 2025-02-12
Enrollment: 120
Sex: ALL
Minimum age (years): 19
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The objective of this clinical trial is to evaluate the safety and efficacy of olanzapine titration schedule in patients with schizophrenia


Eligibility criteria: Inclusion Criteria:

* Of patients with schizophrenia in accordance with DSM(Diagnostic and Statistical Manual of Mental Disorders)-5 diagnostic criteria, who are judged that administration of low dose is more appropriate than initial recommended dose or standard titration dose of olanzapine to consider medical conditions by investigator
* Patients with the duration of schizophrenia for more than 1 year at screening visit(Visit 1)

Exclusion Criteria:

* Patients diagnosed schizophrenia spectrum and other psychotic disorder(e.g. schizoaffective disorder, etc.), bipolar disorder, depressive disorder, etc., in accordance with DSM(Diagnostic and Statistical Manual of Mental Disorders)-5 diagnostic criteria at screening visit(Visit 1)
* Patients with a history of hospitalization for worsening schizophrenia within 12 weeks at screening visit(Visit 1)

Primary outcomes:
measure: The mean change of PANSS(Positive and Negative Syndrome Scale) total score
timeFrame: 1, 2, 3, 5, 9 weeks from baseline(Visit 2)
measure: Incidence of treatment-emergent adverse events
timeFrame: From the administration of investigational products prescribed at baseline(Visit 2) to 11 weeks(Visit 8)
Secondary outcomes:
Other outcomes:
Locations:
city: Daegu
country: Korea, Republic of
facility: Kyungbook National university hospital
city: Guri-si
country: Korea, Republic of
facility: Hanyang University Guri Hospital
Study officials:
References: